Clinical trial
Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients…
NCT00329940 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00329940 |
|---|---|
| Title | Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer |
| Official title | Assessment of Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Having Discontinued Anastrozole Adjuvant Treatment Due to Musculoskeletal Disorders |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 200 |
| Start date | Nov 1, 2005 |
| Primary completion | Jan 1, 2008 |
| First posted | May 25, 2006 |
| Last update posted | Feb 24, 2017 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: